Search

Displaying results 3781 - 3790 of 7062 in total
  1. Drug

    Empesertib

    go.drugbank.com/drugs/DB19473
    Investigational

    Empesertib has a monoisotopic molecular weight of 559.17 Da. … Empesertib is a small molecule drug. The usage of the INN stem '-sertib' in the name indicates that Empesertib is a serine/threonine kinase inhibitor.

  2. Drug

    Ancremonam

    go.drugbank.com/drugs/DB19710
    Investigational

    Ancremonam has a monoisotopic molecular weight of 518.05 Da. … Ancremonam is a small molecule drug. The usage of the INN stem '-monam' in the name indicates that Ancremonam is a monobactam antibiotic.

  3. Drug

    Mevociclib

    go.drugbank.com/drugs/DB21454
    Investigational

    Mevociclib is under investigation in clinical trial NCT03134638 (A Study of SY-1365 in Adult Patients With Advanced Solid Tumors). Mevociclib has a monoisotopic molecular weight of 586.26 Da. … Mevociclib is a small molecule drug. The usage of the INN stem '-ciclib' in the name indicates that Mevociclib is a cyclin dependant kinase inhibitor.

  4. Drug

    Risvodetinib

    go.drugbank.com/drugs/DB21602
    Investigational

    Risvodetinib has a monoisotopic molecular weight of 574.28 Da. … Risvodetinib is a small molecule drug. The usage of the INN stem '-tinib' in the name indicates that Risvodetinib is a tyrosine kinase inhibitor.

  5. Drug

    Omadacycline

    go.drugbank.com/drugs/DB12455
    ApprovedInvestigational

    Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent

  6. Drug

    Rupatadine

    go.drugbank.com/drugs/DB11614
    ApprovedInvestigational

    Rupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria

    Products: RUPATADINA DOC GENERICI
  7. Drug

    Berdazimer

    go.drugbank.com/drugs/DB18712
    Approved

    This decision is based on positive results demonstrated in 2 Phase 3 trials, B-SIMPLE 4 and B-SIMPLE 2, where reduced lesion counts were observed with once-a-day uses of berdazimer.[L49520] … Berdazimer is a polymeric substance consisting of a polysiloxane backbone (Si-O-Si bonds) with covalently bound N-diazeniumdiolate nitric oxide (NO) donors.

  8. Drug

    Pipotiazine

    go.drugbank.com/drugs/DB01621
    ApprovedInvestigationalWithdrawn

    However, it produces a high incidence of extra pyramidal reactions. It is used for the maintenance treatment of chronic non-agitated schizophrenic patients. … Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics.

    Categories: Dopamine D2 Receptor Antagonists
  9. Drug

    Muromonab

    go.drugbank.com/drugs/DB00075
    ApprovedInvestigationalWithdrawn

    Muromonab is 93% monomeric immune globulin G type 2a (IgG2a). … More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method.

  10. Drug

    Cosibelimab

    go.drugbank.com/drugs/DB15770
    ApprovedInvestigational

    Cosibelimab is a human IgG1 lambda monoclonal antibody directed against programmed death ligand-1 (PD-L1). … On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the